12:00 AM
 | 
Jan 27, 2014
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trebananib regulatory update

The European Commission granted Orphan Drug designation to Amgen's trebananib to treat ovarian cancer. The recombinant Fc-peptide...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >